Standard surgical treatment in pancreatic cancer.
نویسندگان
چکیده
Pancreatic cancer is the third leading neoplasm of the gastrointestinal system and has a dismal prognosis. The majority of patients are no more suitable for resection at time of diagnosis due to early development of distant metastases or major infiltrations of adjacent structures. However, due to the resistance of pancreatic cancers against chemoradiation, curative resection represents the only therapy with a potential for cure. For the surgical treatment of pancreatic head cancer, the classical Whipple operation is still the standard procedure but during the last two decades, pylorus-preserving duodenopancreatectomy has been evolved as a more conservative procedure in order to omit the consequences of partial gastrectomy. For cancer of the pancreatic body and tail, distal pancreatectomy or total pancreatectomy represent the current standard treatment. More radical methods like regional pancreatectomy and resection with extended lymph node dissection have failed so far to demonstrate any improvements in long-term survival compared to the standard types of resection. To further improve the treatment of pancreatic cancer, prospectively randomised trials are needed to compare these extended surgical procedures with the standard types of resection.
منابع مشابه
Effect of Diclofenac Suppository on Treatment of Acute Biliary Pancreatitis
Background and Aim: Acute pancreatitis is an inflammatory pancreatic disease that is associated with low or no fibrosis of the pancreas. Standard non-surgical treatment in all patients involves correcting water and electrolyte disorders, pain relief and avoiding pancreatic secretion. Given that pancreatitis is an inflammatory process, and NSAIDs have been shown to modulate inflammatory processe...
متن کاملA surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer.
BACKGROUND The extent of pancreatic resection and lymphadenectomy, both for Kausch-Whipple pancreatoduodenectomy and for left pancreatectomy, is variable between surgeons, according to their training. METHODS On May 30, 1998, a consensus conference on the surgical treatment of pancreatic cancer took place in Castelfranco Veneto, Italy. A group of 29 European surgeons and pathologists, recogni...
متن کاملCapecitabine and Concurrent Radiation in Patients with Locally Advanced Irresectable Pancreatic Cancer
Pancreatic carcinoma is the fourth leading cause of death worldwide [21]. Despite certain advances in diagnosis, surgical procedures and chemotherapy, the prognosis of pancreatic cancer patients remains dismal [27]. Resection of the tumor at an early stage of the disease is the only curative treatment option. Unfortunately, as pancreatic cancer lacks early symptoms, less than 25% of patients un...
متن کاملAn Effective Concentration of 5-Aza-CdR to Induce Cell Death and Apoptosis in Human Pancreatic Cancer Cell Line through Reactivating RASSF1A and Up-Regulation of Bax Genes
Background: Promoter hyper-methylation of tumor suppressor genes is a common event that occurs in cancer. As methylation is a reversible modification, agents capable of reversing an abnormal methylation status should help to combat cancer. 5-Aza-CdR is a DNA methyl-transferase inhibitor. The present study aimed to evaluate the effect of 5-Aza-CdR on the proliferation of human pancreatic cancer ...
متن کاملImmunotherapy of the Pancreatic Cancer
Pancreatic cancer, which we refer to pancreatic ductal adenocarcinoma, is the forth most common cause of cancer-realated-death disease. In 2010, there were 43,140 new cases and 36,800 patients died of pancreatic cancer in USA(1). Although surgical resection may be the only available treatment for this horrible disease, there are beyond 80% patients when dignosised cannot be cured by surgical tr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 10 Suppl 4 شماره
صفحات -
تاریخ انتشار 1999